sotigalimab
apexigen
['sotigalimab', 'gastroesophageal', 'esophageal', 'apexigen']
apexigen presents new data from a phase 2 trial evaluating its cd40 antibody, sotigalimab, in combination with neoadjuvant chemoradiation in patients with resectable esophageal and gastroesophageal junction cancers at esmo congress 2022 
Pharmaceutical News - Direct Information